1. Home
  2. DBVT vs SILC Comparison

DBVT vs SILC Comparison

Compare DBVT & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • SILC
  • Stock Information
  • Founded
  • DBVT 2002
  • SILC 1987
  • Country
  • DBVT France
  • SILC Israel
  • Employees
  • DBVT N/A
  • SILC N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • SILC Computer Manufacturing
  • Sector
  • DBVT Health Care
  • SILC Technology
  • Exchange
  • DBVT Nasdaq
  • SILC Nasdaq
  • Market Cap
  • DBVT 102.0M
  • SILC 91.4M
  • IPO Year
  • DBVT N/A
  • SILC 1994
  • Fundamental
  • Price
  • DBVT $6.46
  • SILC $14.68
  • Analyst Decision
  • DBVT Strong Buy
  • SILC Hold
  • Analyst Count
  • DBVT 2
  • SILC 2
  • Target Price
  • DBVT $22.50
  • SILC N/A
  • AVG Volume (30 Days)
  • DBVT 1.1M
  • SILC 25.6K
  • Earning Date
  • DBVT 05-06-2025
  • SILC 04-28-2025
  • Dividend Yield
  • DBVT N/A
  • SILC N/A
  • EPS Growth
  • DBVT N/A
  • SILC N/A
  • EPS
  • DBVT N/A
  • SILC N/A
  • Revenue
  • DBVT $4,200,000.00
  • SILC $58,114,000.00
  • Revenue This Year
  • DBVT $1,679.52
  • SILC $6.22
  • Revenue Next Year
  • DBVT $535.67
  • SILC $19.10
  • P/E Ratio
  • DBVT N/A
  • SILC N/A
  • Revenue Growth
  • DBVT N/A
  • SILC N/A
  • 52 Week Low
  • DBVT $0.44
  • SILC $11.35
  • 52 Week High
  • DBVT $7.28
  • SILC $18.24
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 65.77
  • SILC 40.88
  • Support Level
  • DBVT $3.91
  • SILC $14.38
  • Resistance Level
  • DBVT $7.28
  • SILC $15.37
  • Average True Range (ATR)
  • DBVT 0.60
  • SILC 0.73
  • MACD
  • DBVT 0.20
  • SILC 0.04
  • Stochastic Oscillator
  • DBVT 75.67
  • SILC 31.76

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

About SILC Silicom Ltd

Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.

Share on Social Networks: